Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has been added to the Russell 3000® and Russell 2000® Indexes, a move that underscores the company’s growing market capitalization and its progress toward the potential FDA approval and launch of TNX-102 SL for fibromyalgia. This inclusion, effective June 30, 2025, is a testament to Tonix’s development trajectory and its commitment to addressing unmet medical needs in pain management and public health challenges.

The Russell indexes are pivotal benchmarks in the investment world, with approximately $10.6 trillion in assets tied to their performance. Tonix’s addition to these indexes is expected to enhance the company’s visibility among investors and stakeholders as it moves closer to commercializing TNX-102 SL. CEO Seth Lederman highlighted the significance of this milestone, emphasizing its role in bolstering Tonix’s profile during a critical phase of its growth.

Tonix Pharmaceuticals is at a pivotal juncture, with plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TNX-102 SL this month. The product candidate, which has shown promising results in two statistically significant phase 3 studies for fibromyalgia management, has also received Fast Track designation from the FDA. Beyond fibromyalgia, TNX-102 SL is being explored for its potential in treating acute stress reaction, showcasing Tonix’s innovative approach to therapy development.

In addition to its advancements in CNS disorders, Tonix is making strides in immunology and infectious diseases, supported by a recent contract from the U.S. Department of Defense for the development of broad-spectrum antiviral agents. With state-of-the-art research and manufacturing facilities, Tonix is well-positioned to continue its trajectory of growth and innovation in the biopharmaceutical sector.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Tonix Pharmaceuticals Added to Russell 3000 and Russell 2000 Indexes.